Abstract: Hormone-receptor-positive advanced breast cancer is an incurable heterogeneous malignant tumor, seriously affecting the health and life of women. The clinical benefit of endocrine follow-up treatment is unsatisfactory due to the changes of tumor biological behavior and its drugs resistance. In recent years, many agents targeting the intracellular signaling pathways associated with endocrine resistance are in development and significantly improve the patients' progression-free survival (PFS) and quality of life, providing more evidence for follow-up endocrine therapy on advanced breast cancer. This article reviews the latest advances in endocrine combination therapy on advanced breast cancer.